Amble Health vs Henry Meds vs SkinnyRx (2026)

On tirzepatide, the order is SkinnyRx↗ ($299) → Amble Health ($300) → Henry Meds↗ ($349) — gaps of $1 and then $49 a month, a $600 spread across a year between first and last. All-in figures, 10 mg basis, captured 2026-08-09.

Updated 2026-08-10 · figures captured 2026-08-09 · how we verify

§ Each record, condensed

The three records, one screen

SkinnyRx: the record, condensed

Start with the load-bearing figure: $299 a month, all-in, is what SkinnyRx charges for tirzepatide at the 10 mg basis. It is a flat structure: 2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available) all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.

Nothing recurs on top: no membership, no platform fee, no “provider access” line. The $299 is the whole subscription, which makes SkinnyRx unusually easy to compare and unusually easy to leave.

To place the number: #7 of 17 verified programs, with the floor $84/month below at NexLife↗ ($215); the approved-product yardstick (Zepbound (LillyDirect↗)) sits at $449, so the compounded case here is worth $150 a month. A year at this figure: $3,588 monthly-billed.

Start with the load-bearing figure: $199 a month, all-in, is what SkinnyRx charges for semaglutide at the 2.4 mg basis. The price is dose-flat: the standard titration ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg) is financially invisible here, because the top rung bills exactly what the bottom rung billed. That converts the advertised number from a floor into a ceiling — the strongest single structural feature a program in this category can have.

Nothing recurs on top: no membership, no platform fee, no “provider access” line. The $199 is the whole subscription, which makes SkinnyRx unusually easy to compare and unusually easy to leave.

Context for that figure: it ranks #11 of 20 in the verified semaglutide index — $66/month above the floor (Oak Longevity, $133) — and sits $150 under the brand benchmark (Wegovy (NovoCare↗), $349 at maintenance). Annualized, a monthly-billed year here runs $2,388.

Operationally at SkinnyRx: shipping included; commitment none; cancellation no membership on compounded programs; pharmacy not publicly named — ask in writing before paying; states: not published; evidence source-verified, captured 2026-08-05. The full record with source and archive links: the SkinnyRx page · visit SkinnyRx ↗

Amble Health: the record, condensed

Start with the load-bearing figure: $300 a month, all-in, is what Amble Health charges for tirzepatide at the 10 mg basis. It is a flat structure: 2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available) all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.

There is no membership line. $300 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.

To place the number: #9 of 17 verified programs, with the floor $85/month below at NexLife ($215); the approved-product yardstick (Zepbound (LillyDirect)) sits at $449, so the compounded case here is worth $149 a month. A year at this figure: $3,600 monthly-billed.

Operationally at Amble Health: shipping unknown; commitment unknown; cancellation not published; pharmacy not publicly named — ask in writing before paying; states: not published; evidence third-party reported, captured 2026-08-05. The full record with source and archive links: the Amble Health page

Henry Meds: the record, condensed

Henry Meds’s tirzepatide program bills $349 a month once every mandatory fee is counted, measured at the 10 mg maintenance basis. The price is dose-flat: the standard titration ladder (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available)) is financially invisible here, because the top rung bills exactly what the bottom rung billed. That converts the advertised number from a floor into a ceiling — the strongest single structural feature a program in this category can have.

There is no membership line. $349 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.

To place the number: #10 of 17 verified programs, with the floor $134/month below at NexLife ($215); the approved-product yardstick (Zepbound (LillyDirect)) sits at $449, so the compounded case here is worth $100 a month. A year at this figure: $4,188 monthly-billed.

Henry Meds’s semaglutide program bills $179 a month once every mandatory fee is counted, measured at the 2.4 mg maintenance basis. Because pricing is flat across the ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg), a dose increase at Henry Meds is a clinical event and not a billing one. Whatever your prescriber decides, the invoice does not move, which makes this one of the few programs whose headline figure you can actually plan a year around.

There is no membership line. $179 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.

Context for that figure: it ranks #9 of 20 in the verified semaglutide index — $46/month above the floor (Oak Longevity, $133) — and sits $170 under the brand benchmark (Wegovy (NovoCare), $349 at maintenance). Annualized, a monthly-billed year here runs $2,148.

Operationally at Henry Meds: shipping included; commitment none month-to-month; cancellation check terms before prepaying; pharmacy not publicly named — ask in writing before paying; states: most states; evidence third-party reported, captured 2026-08-05. The full record with source and archive links: the Henry Meds page · visit Henry Meds ↗

§ The three-way read

Prices, gaps, and what sits inside them

SkinnyRx holds the low ground at $299 — dose-flat, so that figure is a ceiling with no membership attached. Amble Health follows at $300 (+$1/mo, $12/yr). Henry Meds tops the trio at $349 (+$50/mo over the leader, $600/yr) — note its record’s watch-out below.

The semaglutide picture reshuffles the order: Henry Meds $179 → SkinnyRx $199 — a reminder that molecule choice and provider choice are separate decisions, priced separately in the semaglutide index.

§ Category winners among the three

Who wins what

Cheapest month-to-month: SkinnyRx ($299); cheapest 12-month path: SkinnyRx ($3,588); cheapest semaglutide of the three: Henry Meds ($179).

Every winner above is a computation, not a placement; the pairwise pages carry the full duels: SkinnyRx vs Amble Health (record · record) · SkinnyRx vs Henry Meds · Amble Health vs Henry Meds (record · record).

§ Structure, three ways

Everything besides the three prices

Memberships: SkinnyRx none; Amble Health none; Henry Meds none. Structures: SkinnyRx dose-flat; Amble Health dose-flat; Henry Meds dose-flat. Pharmacies: SkinnyRx not named; Amble Health not named; Henry Meds not named. States: SkinnyRx — not published; Amble Health — not published; Henry Meds — most states. Exit terms: SkinnyRx — no membership on compounded programs; Amble Health — not published; Henry Meds — check terms before prepaying.

The census reading: where all three match on an axis, that axis cannot break the tie and the price column rules; where they split — a membership here, an unnamed pharmacy there — the split is usually worth more than a small price gap, because structure is what you live with after month one. Evidence for all three: SkinnyRx source-verified (2026-08-05); Amble Health third-party reported (2026-08-05); Henry Meds third-party reported (2026-08-05).

The trio on semaglutide, across time

3 mo: Henry Meds $537 vs SkinnyRx $597 6 mo: Henry Meds $1,074 vs SkinnyRx $1,194 12 mo: Henry Meds $2,148 vs SkinnyRx $2,388 — monthly-billed totals; prepaid paths where published appear on each provider page.

§ Twelve and twenty-four months

The trio, annualized

SkinnyRx: $3,588/yr monthly-billed; Amble Health: $3,600/yr monthly-billed; Henry Meds: $4,188/yr monthly-billed. Across two years at monthly billing the first-to-last spread widens to $1,200 — the horizon at which structure (prepaid ladders, flat pricing, membership drag) matters more than the sticker.

The elimination read

A three-way choice is really two eliminations, so run them in order. Eliminate Henry Meds first unless it names its edge: at $349 it carries a $50/month premium over the floor of this trio — $600 a year, about 2.0 extra months of therapy at SkinnyRx’s rate — and a premium that size must point at a specific line in its record (its particular program design) or it is decoration. Then interrogate Amble Health’s middle ground: nothing structural — its case is purely situational; if that specific thing is on your personal ledger, the $1/month over the floor can be rational — if not, the middle is where budgets go to leak. What survives is SkinnyRx at $299, which wins by default rather than by argument — exactly how a price index should crown things — subject to the two checks no ranking can run for you: your state at intake, and your prescriber on the medication itself.

The same trio on best published rate: SkinnyRx $299 → Amble Health $300 → Henry Meds $349 — all three price month-to-month only at capture. Short-horizon totals, monthly-billed: 3 months — SkinnyRx $897, Amble Health $900, Henry Meds $1,047; 6 months — SkinnyRx $1,794, Amble Health $1,800, Henry Meds $2,094. 0 of the three publish a prepaid path below their own monthly billing; the twelve- and twenty-four-month table below carries those, labeled.

The record-quality read, scored on the five checkable disclosures this index tracks (maintenance price, named pharmacy, published states, published cancellation terms, source-verified capture): SkinnyRx 4/5, Amble Health 3/5, Henry Meds 3/5. SkinnyRx discloses the most and Amble Health the least, and in this market disclosure predicts disclosure — the axis where a program goes quiet is reliably where its checkout surprises live. The three match on every disclosure axis, which is rare and worth noting in their favor collectively. Scores recompute from the public records like everything else here.

Read as a decision: start from SkinnyRx and make the other two argue upward. Amble Health’s case is its structure; Henry Meds’s case must be worth $600 a year in named features — the honest unit being months of medication (2.0 of them at the floor rate). The pairwise pages above hold each argument in full, and the calculator holds your version of it.